title: Radiation-enhancing effect of sodium glycididazole in patients suffering from non-small cell lung cancer with multiple brain metastases: A randomized, placebo-controlled study.
abstract: OBJECTIVE
  Median survival of patients with brain metastases from non-small cell lung cancer is poor. This study was to investigate the radiation-enhancing effect of sodium glycididazole combined with whole-brain radiotherapy of multiple brain metastases from non-small cell lung cancer.
  
  
  METHODS
  Sixty-four patients with multiple brain metastases from non-small cell lung cancer were included: the study group (n=32) received whole-brain radiotherapy combined with sodium glycididazole at a dose of 700mg/m(2) intravenous infusion 30minutes before radiotherapy, three times a week; the control group (n=32) only received whole-brain radiotherapy. The primary end point was central nervous system (CNS) progression-free survival and overall survival. The treatment-related toxicity was also recorded.
  
  
  RESULTS
  The CNS disease control rate was better (90.6% vs 65.6%, P=0.016) in the study group than in the control group at 3 month of follow-up. The median CNS progression-free survival time was longer in the study group than in the control group (7.0 months vs 4.0 months, P=0.038). There was no significant difference of the median overall survival time between the study group and the control group (11.0 months vs 9.0 months, P=0.418). On the other hand, the treatment-related toxicity showed no statistically significant difference between these two groups (P>0.05).
  
  
  CONCLUSIONS
  The study indicated that sodium glycididazole was an effective, promising radiation-enhancing agent that improved CNS disease control rate, extended the median CNS progression-free survival time and was well tolerated in patients suffering from non-small cell lung cancer with multiple brain metastases.
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: Y C
authors.initials: YC
authors.lastname: Zeng
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China. Electronic address: 511695796@qq.com.
authors.forename: R
authors.initials: R
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: R
authors.initials: R
authors.lastname: Xing
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: F
authors.initials: F
authors.lastname: Chi
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: S L
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: X D
authors.initials: XD
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Xuan
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: L N
authors.initials: LN
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: Q Y
authors.initials: QY
authors.lastname: Duan
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: M Y
authors.initials: MY
authors.lastname: Tang
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: N
authors.initials: N
authors.lastname: Niu
authors.affiliation: Department of Medical Oncology, Cancer Center, Shengjing Hospital of China Medical University, 39, Huaxiang Road, Shenyang 110022, China.
authors.forename: Y N
authors.initials: YN
authors.lastname: Sun
authors.affiliation: Department of Otorhinolaryngology, Harbin First Hospital, 151, Diduan Street, Harbin 150010, China.
authors.forename: G L
authors.initials: GL
authors.lastname: Fan
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China.
authors.forename: H M
authors.initials: HM
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
chemical_list: D007093:Imidazoles; D011838:Radiation-Sensitizing Agents; C000603632:sodium glycididazole
keywords: Agent radiosensibilisant; Cancer du poumon non à petites cellules; Glycididazole de sodium; Non-small cell lung cancer; Radiation-enhancing agent; Sodium glycididazole